

Discovery of dual A2A adenosine receptor agonist/A3 adenosine antagonist as anti-obesity drug

College of pharmacy, Seoul National University



METABOLIC	Lead
Product Type	Small molecule
Indication	Obesity
Target	Adenosine receptor
MoA(Mechanism of Action)	Activation of Adenosine receptor in adipose tissue
Competitiveness	Oral administration provides preference to patients / No CNS-mediated effect / First-in-class Anti-obesity drug / Targeting adipose tissue directly to reduce fat
Development Stage	Lead
Route of Administration	Oral administration